Your browser doesn't support javascript.
loading
A multi-classifier system integrated by clinico-histology-genomic analysis for predicting recurrence of papillary renal cell carcinoma.
Huang, Kang-Bo; Gui, Cheng-Peng; Xu, Yun-Ze; Li, Xue-Song; Zhao, Hong-Wei; Cao, Jia-Zheng; Chen, Yu-Hang; Pan, Yi-Hui; Liao, Bing; Cao, Yun; Zhang, Xin-Ke; Han, Hui; Zhou, Fang-Jian; Liu, Ran-Yi; Chen, Wen-Fang; Jiang, Ze-Ying; Feng, Zi-Hao; Jiang, Fu-Neng; Yu, Yan-Fei; Xiong, Sheng-Wei; Han, Guan-Peng; Tang, Qi; Ouyang, Kui; Qu, Gui-Mei; Wu, Ji-Tao; Cao, Ming; Dong, Bai-Jun; Huang, Yi-Ran; Zhang, Jin; Li, Cai-Xia; Li, Pei-Xing; Chen, Wei; Zhong, Wei-De; Guo, Jian-Ping; Liu, Zhi-Ping; Hsieh, Jer-Tsong; Xie, Dan; Cai, Mu-Yan; Xue, Wei; Wei, Jin-Huan; Luo, Jun-Hang.
Afiliação
  • Huang KB; Department of Urology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Gui CP; Department of Urology, Sun Yat-sen University Cancer center, Guangzhou, China.
  • Xu YZ; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer center, Guangzhou, China.
  • Li XS; Department of Urology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Zhao HW; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Cao JZ; Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China.
  • Chen YH; Department of Urology, Affiliated Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.
  • Pan YH; Department of Urology, Jiangmen Hospital, Sun Yat-sen University, Jiangmen, China.
  • Liao B; Department of Urology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Cao Y; Department of Urology, The Third Affiliated Hospital of Soochow University, Changzhou, China.
  • Zhang XK; Department of Pathology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Han H; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer center, Guangzhou, China.
  • Zhou FJ; Department of Pathology, Sun Yat-sen University Cancer center, Guangzhou, China.
  • Liu RY; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer center, Guangzhou, China.
  • Chen WF; Department of Pathology, Sun Yat-sen University Cancer center, Guangzhou, China.
  • Jiang ZY; Department of Urology, Sun Yat-sen University Cancer center, Guangzhou, China.
  • Feng ZH; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer center, Guangzhou, China.
  • Jiang FN; Department of Urology, Sun Yat-sen University Cancer center, Guangzhou, China.
  • Yu YF; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer center, Guangzhou, China.
  • Xiong SW; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer center, Guangzhou, China.
  • Han GP; Department of Pathology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Tang Q; Department of Pathology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Ouyang K; Department of Urology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Qu GM; Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
  • Wu JT; Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China.
  • Cao M; Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China.
  • Dong BJ; Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China.
  • Huang YR; Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China.
  • Zhang J; Department of Urology, Affiliated Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.
  • Li CX; Department of Pathology, Affiliated Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.
  • Li PX; Department of Urology, Affiliated Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.
  • Chen W; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Zhong WD; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Guo JP; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Liu ZP; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Hsieh JT; School of Mathematics and Computational Science, Sun Yat-sen University, Guangzhou, China.
  • Xie D; School of Mathematics and Computational Science, Sun Yat-sen University, Guangzhou, China.
  • Cai MY; Department of Urology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Xue W; Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
  • Wei JH; Institute of Precision Medicine, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Luo JH; Department of Internal Medicine and Department of Molecular Biology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA.
Nat Commun ; 15(1): 6215, 2024 Jul 23.
Article em En | MEDLINE | ID: mdl-39043664
ABSTRACT
Integrating genomics and histology for cancer prognosis demonstrates promise. Here, we develop a multi-classifier system integrating a lncRNA-based classifier, a deep learning whole-slide-image-based classifier, and a clinicopathological classifier to accurately predict post-surgery localized (stage I-III) papillary renal cell carcinoma (pRCC) recurrence. The multi-classifier system demonstrates significantly higher predictive accuracy for recurrence-free survival (RFS) compared to the three single classifiers alone in the training set and in both validation sets (C-index 0.831-0.858 vs. 0.642-0.777, p < 0.05). The RFS in our multi-classifier-defined high-risk stage I/II and grade 1/2 groups is significantly worse than in the low-risk stage III and grade 3/4 groups (p < 0.05). Our multi-classifier system is a practical and reliable predictor for recurrence of localized pRCC after surgery that can be used with the current staging system to more accurately predict disease course and inform strategies for individualized adjuvant therapy.
Assuntos

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais / Recidiva Local de Neoplasia Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais / Recidiva Local de Neoplasia Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China